Cargando…

Mutation of TP53, translocation analysis and immunohistochemical expression of MYC, BCL-2 and BCL-6 in patients with DLBCL treated with R-CHOP

Diffuse large B-cell lymphoma (DLBCL) is an aggressive lymphoma with diverse outcomes. Concurrent translocation of MYC and BCL-2 and/or BCL-6, and concurrent immunohistochemical (IHC) high expression of MYC and BCL-2, have been linked to unfavorable treatment responses. TP53-mutated DLBCL has also b...

Descripción completa

Detalles Bibliográficos
Autores principales:	Peroja, Pekka, Pedersen, Mette, Mantere, Tuomo, Nørgaard, Peter, Peltonen, Jenni, Haapasaari, Kirsi-Maria, Böhm, Jan, Jantunen, Esa, Turpeenniemi-Hujanen, Taina, Rapakko, Katrin, Karihtala, Peeter, Soini, Ylermi, Vasala, Kaija, Kuittinen, Outi
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2018
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6172218/ https://www.ncbi.nlm.nih.gov/pubmed/30287880 http://dx.doi.org/10.1038/s41598-018-33230-3

Ejemplares similares

Oxidative stress and redox state-regulating enzymes have prognostic relevance in diffuse large B-cell lymphoma
por: Peroja, Pekka, et al.
Publicado: (2012)

Integrin alpha 10, CD44, PTEN, cadherin-11 and lactoferrin expressions are potential biomarkers for selecting patients in need of central nervous system prophylaxis in diffuse large B-cell lymphoma
por: Lemma, Siria A, et al.
Publicado: (2017)

Nuclear factor erythroid 2-related factors 1 and 2 are able to define the worst prognosis group among high-risk diffuse large B cell lymphomas treated with R-CHOEP
por: Kari, Esa, et al.
Publicado: (2019)

Impact of central nervous system (CNS) prophylaxis on the incidence of CNS relapse in patients with high-risk diffuse large B cell/follicular grade 3B lymphoma
por: Kuitunen, Hanne, et al.
Publicado: (2020)

Antithrombin III is probably not a suitable biomarker for diagnosis of primary central nervous system lymphoma
por: Kuusisto, Milla Elvi Linnea, et al.
Publicado: (2015)

Significance of bulky mass and residual tumor—Treated with or without consolidative radiotherapy—To the risk of relapse in DLBCL patients
por: Tokola, Susanna, et al.
Publicado: (2020)

Interim and end‐of‐treatment PET‐CT suffers from high false‐positive rates in DLBCL: Biopsy is needed prior to treatment decisions
por: Tokola, Susanna, et al.
Publicado: (2021)

Keap1 expression has independent prognostic value in pancreatic adenocarcinomas
por: Isohookana, Joel, et al.
Publicado: (2015)

Redox Regulating Enzymes and Connected MicroRNA Regulators Have Prognostic Value in Classical Hodgkin Lymphomas
por: Karihtala, Peeter, et al.
Publicado: (2017)

High-level cytoplasmic claudin 3 expression is an independent predictor of poor survival in triple-negative breast cancer
por: Jääskeläinen, Anniina, et al.
Publicado: (2018)

Combination of Strong MMP-2 and Weak TIMP-2 Immunostainings Is a Significant Prognostic Factor in Endometrial Carcinoma
por: Honkavuori-Toivola, Maria, et al.
Publicado: (2013)

Reactive Oxygen Species-Mediated Mechanisms of Action of Targeted Cancer Therapy
por: Teppo, Hanna-Riikka, et al.
Publicado: (2017)

Testis-Specific Thioredoxins TXNDC2, TXNDC3, and TXNDC6 Are Expressed in Both Testicular and Systemic DLBCL and Correlate with Clinical Disease Presentation
por: Chan, Mikko C., et al.
Publicado: (2021)

Oxidative stress and counteracting mechanisms in hormone receptor positive, triple-negative and basal-like breast carcinomas
por: Karihtala, Peeter, et al.
Publicado: (2011)

Snail promotes an invasive phenotype in lung carcinoma
por: Merikallio, Heta, et al.
Publicado: (2012)

Clinical impact of ibrutinib plus R-CHOP in untreated DLBCL coexpressing BCL2 and MYC in the phase 3 PHOENIX trial
por: Johnson, Peter W. M., et al.
Publicado: (2023)

Blood Graft and Outcome After Autologous Stem Cell Transplantation in Patients With Primary Central Nervous System Lymphoma
por: Partanen, Anu, et al.
Publicado: (2021)

Quantitative analysis of tumor-specific BCL2 expression in DLBCL: refinement of prognostic relevance of BCL2
por: Roh, Jin, et al.
Publicado: (2020)

Primary central nervous system lymphoma high incidence and poor survival in Finnish population-based analysis
por: Puhakka, Inka, et al.
Publicado: (2022)

Molecularly Stratified Treatment Options in Primary Refractory DLBCL/HGBL with MYC and BCL2 or BCL6 Rearrangements (HGBL, NOS with MYC/BCL6)
por: Witte, Hanno M., et al.
Publicado: (2023)

The Role of Redox-Regulating Enzymes in Inoperable Breast Cancers Treated with Neoadjuvant Chemotherapy
por: Roininen, Nelli, et al.
Publicado: (2017)

BCL10 Mutations Define Distinct Dependencies Guiding Precision Therapy for DLBCL
por: Xia, Min, et al.
Publicado: (2022)

CD34(+) Cell Mobilization, Autograft Cellular Composition and Outcome in Mantle Cell Lymphoma Patients
por: Turunen, Antti Samuli, et al.
Publicado: (2023)

GNA13 regulates BCL2 expression and the sensitivity of GCB-DLBCL cells to BCL2 inhibitors in a palmitoylation-dependent manner
por: Xia, Zhizhou, et al.
Publicado: (2021)

Levels of Circulating TIMP-2 and MMP2-TIMP2 Complex Are Decreased in Squamous Cervical Carcinoma
por: Anne, Talvensaari-Mattila, et al.
Publicado: (2010)

p53 in head and neck cancer: Functional consequences and environmental implications of TP53 mutations
por: Peltonen, Jenni K, et al.
Publicado: (2010)

Somatic copy number gains in MYC, BCL2, and BCL6 identifies a subset of aggressive alternative-DH/TH DLBCL patients
por: Krull, Jordan E., et al.
Publicado: (2020)

Real world data on young patients with high-risk diffuse large B-cell lymphoma treated with R-CHOP or R-CHOEP - MYC, BCL2 and BCL6 as prognostic biomarkers
por: Pedersen, Mette Ølgod, et al.
Publicado: (2017)

Chidamide induces apoptosis in DLBCL cells by suppressing the HDACs/STAT3/Bcl-2 pathway
por: Zhang, Hongwei, et al.
Publicado: (2021)

Specific TP53 mutations predict aggressive phenotype in head and neck squamous cell carcinoma: a retrospective archival study
por: Peltonen, Jenni K, et al.
Publicado: (2011)

The Sample Type used Affects the Levels of Gelatinases (MMP-2 and -9) and their Inhibitors (TIMP-1 and -2) in Circulating Blood of Healthy Controls and Breast Cancer Patients
por: Paula, Kuvaja, et al.
Publicado: (2007)

Overexpression of BCL2, BCL6, VEGFR1 and TWIST1 in Circulating Tumor Cells Derived from Patients with DLBCL Decreases Event-Free Survival
por: Cerón, Rafael, et al.
Publicado: (2022)

DLBCL 1L—What to Expect beyond R-CHOP?
por: Stegemann, Maike, et al.
Publicado: (2022)

Role of MYC and BCL2 expression in a cohort of 43 patients with DLBCL: a retrospective study
por: Khan, Umair Tahir, et al.
Publicado: (2021)

Serpentine Supravenous Hyperpigmentation in an HIV Patient Receiving R-CHOP for DLBCL
por: Lancman, Guido, et al.
Publicado: (2018)

Targeting of Inflammatory Pathways with R2CHOP in High-Risk DLBCL
por: Hartert, Keenan T., et al.
Publicado: (2020)

NRF3 Decreases during Melanoma Carcinogenesis and Is an Independent Prognostic Marker in Melanoma
por: Immonen, Anni, et al.
Publicado: (2022)

Inhibition of acylglycerol kinase sensitizes DLBCL to venetoclax via upregulation of FOXO1-mediated BCL-2 expression
por: Ning, Na, et al.
Publicado: (2022)

CHOP mediates ASPP2-induced autophagic apoptosis in hepatoma cells by releasing Beclin-1 from Bcl-2 and inducing nuclear translocation of Bcl-2
por: Liu, K, et al.
Publicado: (2014)

Mutational signatures and their association with survival and gene expression in urological carcinomas
por: Karihtala, Peeter, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_vmj0iqurmjpkov2bktmog99gd2